ACHL (Achilles Therapeutics) Total Stockholders Equity : $103.14 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Total Stockholders Equity?

Achilles Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $103.14 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Achilles Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $2.51. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Achilles Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.04.

Achilles Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Achilles Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Total Stockholders Equity Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

101.35

189.37

289.53

197.04

142.37

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															153.49	142.37	130.35	115.48	103.14

Achilles Therapeutics (NAS:ACHL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Achilles Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(103.138	-	0)	/	41.100
	=	2.51

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Achilles Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.62	+	0)	/	103.138
	=	0.04

Achilles Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.